StockNews.AI

182,827 Orion Corporation A shares converted into B shares

StockNews.AI • 1 minute

VRTXGILD
High Materiality7/10

Information

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE...

Original source

AI Summary

On January 16, 2026, Orion Corporation converted 182,827 A shares into B shares, affecting its share structure. With total shares now at 141,134,278 and a strong focus on oncology and pain treatment areas, the company's financial performance remains solid, stated by 2024 sales of EUR 1,542 million.

Sentiment Rationale

Conversions typically have limited direct market impact but can enhance share liquidity. Historical performances show similar actions lead to moderate price adjustments.

Trading Thesis

Orion Corporation's share conversion and solid financials position it for growth; consider a long position.

Market-Moving

  • Share conversion may increase liquidity and trading activity.
  • Positive sales growth can attract institutional investments.
  • Continued focus on oncology may lead to future product launches.
  • Global health trends could enhance Orion’s market presence.

Key Facts

  • 182,827 A shares converted into B shares.
  • Total shares now 141,134,278 post-conversion.
  • Orion's focus includes oncology and pain treatments.
  • 2024 net sales reached EUR 1,542 million.
  • Company employs about 3,700 worldwide.

Companies Mentioned

  • Orion Corporation (ORN): Focus on transforming share structure may enhance investor interest.

Corporate Developments

The focus on share conversion fits 'Corporate Developments' as it impacts stock liquidity and may influence share price activity. This strategic move aligns with broader corporate governance initiatives and liquidity management.

Orion Corporation Announces Conversion of Shares

Date: January 16, 2026 | Source: Orion Oyj

Overview of Share Conversion

On January 16, 2026, Orion Corporation (stock symbol: ORN) announced a significant corporate action involving the conversion of 182,827 A shares into 182,827 B shares. This conversion, as stipulated in Section 3 of Orion's Articles of Association, has been officially recorded in the Trade Register.

Current Share Structure

Following this adjustment, the total number of shares in Orion Corporation is now 141,134,278. The breakdown of shares is as follows:

  • 31,587,492 A shares
  • 109,546,786 B shares

The total number of votes associated with the company's shares now stands at 741,296,626.

Leadership Insights

Liisa Hurme, President and CEO of Orion Corporation, emphasized the importance of this conversion for the company’s share structure. Additionally, General Counsel Mikko Kemppainen supports this strategic move aimed at enhancing shareholder value.

For further details, investors can contact Tuukka Hirvonen, Head of Investor Relations, at +358 10 426 2721.

About Orion Corporation

Orion Corporation is a leading Nordic pharmaceutical company with over a century of experience in promoting well-being. The organization focuses on the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients. Key areas of research and development include:

  • Oncology
  • Pain management

Orion offers a diverse range of proprietary and generic medicines along with consumer health products. In 2024, Orion reported net sales of EUR 1,542 million and employed approximately 3,700 professionals dedicated to advancing public health.

Orion's A and B shares are publicly traded on Nasdaq Helsinki, providing a transparent investment opportunity.

Related News